Navigation Links
Amgen Announces 2012 Third Quarter Dividend
Date:7/19/2012

both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain;
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
... N.J., April 25 Osteotech, Inc.,(Nasdaq: OSTE ), ... for,regenerative medicine, announced today that the United States Food ... the Plexur,P(TM) Biocomposite for use in spinal applications as ... Previously, Osteotech received FDA clearance for,Plexur P(TM) for use ...
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... held April 30 - May 2, 2008, at ... Executive Officer, will,attend. His presentation is scheduled for ...
Cached Biology Technology:Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 2Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 3
(Date:4/24/2014)... Have you ever accidently missed a red light or ... a visible event that you passed by but totally ... for our attention, we can only be aware of ... Beckman Institute Postdoctoral Fellow at the University of Illinois. ... concentrating on obeying traffic signals." , But say there,s ...
(Date:4/24/2014)... attack plants, they often inject harmful proteins into ... natural defenses. However, in some plants, bacteria attack ... potential host. Now, researchers at the University of ... allows the bacteriaknown mostly for attacking tomatoesto invade ... anti-infective treatments that work with food-producing plants to ...
(Date:4/24/2014)... Alison Allan, PhD, a scientist at Western University and ... often spreads or metastasizes to the lung. , Breast ... number two cause of cancer-related deaths among women in ... radiation have a high success rate, but once the ... In particular, the lung is one of the most ...
Breaking Biology News(10 mins):Controlling brain waves to improve vision 2Controlling brain waves to improve vision 3Plants send out signals attracting harmful bacteria, MU study finds 2New study helps to explain why breast cancer often spreads to the lung 2
... The American Association for Cancer Research will host its ... Disparities from Sept. 18-21, 2011, in the Grand Hyatt ... will bring together scientists, survivors, doctors and others to ... treatment methods to better meet the needs of underserved ...
... have employed pheromone-baited bucket traps, canines to sniff out ... to eradicate the coconut rhinoceros beetle (CRB) on Guam ... to these tactics. USDA has given Guam an infusion ... rhino beetle population on island. Aubrey Moore, entomologist and ...
... of American Societies for Experimental Biology (FASEB) announced today ... (HCS). The executive leadership has retained FASEB to ... membership marketing, recruitment, and retention, as well as a ... William Stahl, PhD commented, "HCS is pleased to have ...
Cached Biology News:AACR to host conference on the science of cancer health disparities 2